The study comprised 58 patients in stage III or IV NSCLC who received either a combination of the virus targeting the p53 gene (intervention arm) and chemotherapy through the bronchial artery or chemotherapy alone (control arm). Here, TP53 is linked to non-small cell lung carcinoma.